The influence of preoperative pharmacotherapy on the appearance of postoperative atrial fibrillation in patients undergoing isolated coronary artery bypass grafting

Milica V. Vukicevic¹, Svetozar Putnik²,³, Tatjana S. Potpara¹,³

¹Cardiology Clinic, Clinical Centre of Serbia, ²Cardiac Surgery Clinic, Clinical Centre of Serbia, ³School of Medicine, Belgrade University, Belgrade, Serbia

Abstract

Introduction: Postoperative atrial fibrillation (POAF) is the most common arrhythmia post coronary artery bypass grafting (CABG). It is associated with an increased morbidity and mortality. Published studies have yielded conflicting results considering the association of preoperative pharmacotherapy with POAF. We assessed the relationship of preoperative medication with POAF in patients undergoing isolated CABG.

Methods: We retrospectively studied 226 consecutive patients without history of prior AF, undergoing CABG from September to December 2014. All patients underwent continuous telemetry for ≥5 postoperative days, and POAF was documented using 12-channel electrocardiography. We used univariate and multivariable Logistic regression analyses (adjusted for demographics, cardiovascular risk factors, and the CABG procedure type) to analyse the relationship of preoperative pharmacotherapy with the occurrence of POAF.

Results: Of 226 patients (mean age: 63.9±7.9 years, female n=54, 23.9%), 53 (23.5%) experienced ≥1 POAF episode until discharge. They were older (65.8±7.3 vs. 63.4±8.0; p=0.049) and less often were taking statins preoperatively compared to non-POAF patients (n=39, 73.6% vs. n=137, 87.2%; p=0.030). There were no significant differences between the groups considering concomitant preoperative comorbidities (e.g., arterial hypertension, diabetes mellitus, chronic obstructive pulmonary disease, etc.), smoking or preoperative medication including amiodarone, beta-blockers, digoxin, diuretics, spironolactone, angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and Ca-antagonists. In a multivariable analysis, preoperative statin use was associated with a 60% risk reduction in POAF incidence (Odds Ratio 0.41; 95% CI 0.19-0.87; p=0.020).

Conclusion: We found that preoperative use of statins may reduce the incidence of POAF in patients undergoing isolated CABG.

Key Words

postoperative atrial fibrillation, CABG, preoperative pharmacotherapy, statins.
conventional on-pump coronary artery bypass grafting and the advent of off-pump CABG rassed the expectation that there would be a strikingly lower incidence of POAF. However, more recent studies demonstrated that POAF occurred with similar frequencies irrespective of the method of revascularization used, after adjusting for differences in baseline, and perioperative variables.3

Risk factors for POAF could be grouped into pre-, intra- and postoperative. Preoperative factors mainly include: sex, age, body mass index, type of coronary artery disease, stage of systolic dysfunction, preoperative AF or myocardial infarction, preoperative echocardiographic parameters and well known risk factors for coronary artery disease: arterial hypertension (HTA), diabetes mellitus (DM), dyslipidemia (HLP), chronic lung disease (COPD), preoperative transient ischemic attack or cerebrovascular insult (TIA/CVI), peripheral arterial disease (PAD) and smoking. Intraoperative factors are: number, type and location of bypass grafts, time of extracorporeal circulation usage and cross-clamp time. Postoperative factors could be the postoperative use of inotropes and postoperative value of troponin.2

Consequently, effective treatment for the prevention of POAF is of vital importance. Numerous pharmacologic strategies attempt to reduce the incidence of POAF. Overall, most reported studies demonstrate a positive effect with a variety of pharmacologic agents either anti-arrhythmic (amiodarone, beta-blockers, digoxin, ACEi/ARBs, calcium-antagonists) or non-antiarrhythmic drugs (non-steroidal anti-inflammatory drugs, corticosteroids, statins). To date, however, no single agent or combination of agents has completely eliminated POAF.3 Studies of treatments to reduce the risk of POAF have yielded conflicting results.

The aim of this study was to investigate the relationship of preoperative pharmacotherapy with the occurrence of POAF in patients undergoing CABG.

Methods

This retrospective study, conducted from September to December 2014, included 226 consecutive patients without history of prior AF, scheduled for CABG (off-pump/on-pump) at CardioSurgery Clinic, Clinical Centre of Serbia. All patients underwent continuous telemetry for ≥5 postoperative days (until discharge) and POAF was documented using 12-channel electrocardiography. All patients were divided into two groups: 1) POAF patients (N 53; 23.5%) and 2) non-POAF patients (N 173; 76.5%). In both groups we investigated the influence of preoperative pharmacotherapy (amiodarone, beta-blockers, digoxin, diuretics, spironolactone, ACEi/ARBs, calcium-antagonists, statins) on the incidence of POAF. The exclusion criteria were severe mitral regurgitation and preoperative AF.

Statistical analysis. The relationship of preoperative pharmacotherapy with the occurrence of POAF was investigated using univariate and multivariable Logistic regression analyses, adjusted for demographic characteristics (age, sex), cardiovascular risk factors (arterial hypertension [HTA], diabetes mellitus [DM], dyslipidemia [HLP], chronic lung disease [COPD], preoperative transient ischemic attack or cerebrovascular insult [TIA/CVI], peripheral arterial disease [PAD] and smoking), and the type of CABG procedure (off-pump, on-pump).

Results

Of 226 consecutive patients undergoing isolated CABG (mean age: 63.9±7.9 years), 54 patients were female (23.9%). During the in-hospital monitoring 53 patients (23.5%) experienced ≥1 episode of POAF. Patients with POAF were older (65.8±7.3 vs. 63.4±8.0; p=0.049) and less often were taking statins preoperatively.

### Table 1. Differences between the groups considering other preoperative factors

<table>
<thead>
<tr>
<th>Variable</th>
<th>All n (%)</th>
<th>POAF n (%)</th>
<th>non-POAF n (%)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>63.9±7.9</td>
<td>65.8±7.3</td>
<td>63.4±8.0</td>
<td>0.049</td>
</tr>
<tr>
<td>Female sex</td>
<td>54 (23.9%)</td>
<td>10 (18.9%)</td>
<td>44 (25.4%)</td>
<td>0.363</td>
</tr>
<tr>
<td>Hypertension</td>
<td>222 (98.2%)</td>
<td>50 (94.3%)</td>
<td>172 (99.4%)</td>
<td>0.041</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>99 (43.8%)</td>
<td>19 (35.8%)</td>
<td>80 (46.2%)</td>
<td>0.207</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>197 (87.2%)</td>
<td>46 (86.8%)</td>
<td>151 (87.3%)</td>
<td>0.544</td>
</tr>
<tr>
<td>COPD</td>
<td>27 (11.9%)</td>
<td>9 (17.0%)</td>
<td>18 (10.4%)</td>
<td>0.226</td>
</tr>
<tr>
<td>Stroke/TIA</td>
<td>22 (9.7%)</td>
<td>4 (7.5%)</td>
<td>18 (10.4%)</td>
<td>0.791</td>
</tr>
<tr>
<td>PAD</td>
<td>44 (19.5%)</td>
<td>10 (18.9%)</td>
<td>34 (19.7%)</td>
<td>1.000</td>
</tr>
<tr>
<td>Smoking status</td>
<td>104 (46.0%)</td>
<td>22 (41.5%)</td>
<td>82 (47.4%)</td>
<td>0.529</td>
</tr>
</tbody>
</table>

COPD- chronic obstructive pulmonary disease; TIA- transient ischemic attack; PAD- peripheral artery disease.

### Table 2 Differences between the groups considering medications.

<table>
<thead>
<tr>
<th>Variable</th>
<th>All n (%)</th>
<th>POAF n (%)</th>
<th>non-POAF n (%)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amiodarone</td>
<td>15 (6.6%)</td>
<td>4 (7.5%)</td>
<td>11 (6.4%)</td>
<td>0.756</td>
</tr>
<tr>
<td>Beta-blockers</td>
<td>193 (85.4%)</td>
<td>44 (83.0%)</td>
<td>149 (86.1%)</td>
<td>0.657</td>
</tr>
<tr>
<td>Digoxin</td>
<td>1.0 (0.4%)</td>
<td>0 (0.0%)</td>
<td>1 (0.6%)</td>
<td>1.000</td>
</tr>
<tr>
<td>Diuretics</td>
<td>90 (39.8%)</td>
<td>2 (41.5%)</td>
<td>88 (39.3%)</td>
<td>0.873</td>
</tr>
<tr>
<td>Spironolactone</td>
<td>34 (15.0%)</td>
<td>10 (18.9%)</td>
<td>24 (13.9%)</td>
<td>0.384</td>
</tr>
<tr>
<td>ACEI/ARBs</td>
<td>183 (81.0%)</td>
<td>45 (84.9%)</td>
<td>138 (79.8%)</td>
<td>0.549</td>
</tr>
<tr>
<td>Ca antagonists</td>
<td>57 (25.2%)</td>
<td>14 (26.4%)</td>
<td>43 (24.9%)</td>
<td>0.857</td>
</tr>
<tr>
<td>Statins</td>
<td>189 (84.0%)</td>
<td>39 (73.6%)</td>
<td>150 (87.2%)</td>
<td>0.030</td>
</tr>
</tbody>
</table>

ACEi- angiotensin-converting enzyme inhibitors; ARBs- angiotensin II receptor blockers.

### Table 3 Differences between the groups considering the use of on-pump or off-pump surgery.

<table>
<thead>
<tr>
<th>Variable</th>
<th>All n (%)</th>
<th>POAF n (%)</th>
<th>non-POAF n (%)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>ON-PUMP surgery</td>
<td>176 (77.9%)</td>
<td>39 (73.6%)</td>
<td>137 (79.2%)</td>
<td>0.450</td>
</tr>
<tr>
<td>OFF-PUMP surgery</td>
<td>50 (22.1%)</td>
<td>14 (26.4%)</td>
<td>36 (20.8%)</td>
<td>0.450</td>
</tr>
</tbody>
</table>
compared to non-POAF patients (n=39, 73.6% vs. n=137, 87.2%; p=0.030). There were no significant differences between the groups considering other preoperative factors or medications in POAF vs. non-POAF patients (Table 1 and Table 2). In addition, there was no difference in the use of on-pump or off-pump surgery in the POAF vs. non-POAF group (p=0.450) (Table 3).

In a multivariable analysis, adjusted for demographic characteristics (age, sex), cardiovascular risk factors (HTA, DM, HLP, COPD, preoperative TIA/CVI, PAD and smoking), and the type of CABG procedure (off-pump, on-pump), preoperative statin use was associated with a 60% risk reduction in POAF incidence (Odds Ratio 0.41; 95% CI 0.19-0.87; p=0.020).

**Discussion**

In our study 23.5% of all patients experienced ≥1 episode of POAF. Guenancia et al. reported similar results in their study. They included 100 patients (44.64%), with all inclusion criteria, underwent Holter ECG monitoring for 7 days, in order to diagnose also silent POAF, which was defined as the occurrence of POAF on the Holter ECG recording in the absence of any mention of AF in the medical file during the first 7 days of the hospital stay, that was analyzed after hospital discharge. In contrast, clinical POAF (whether symptomatic or not) was defined as any AF episode diagnosed by a physician during the hospital stay. Among them, 21 (21%) developed clinical AF and 13 (13%) developed silent AF as detected by Holter monitoring.4

In our study, patients with POAF were older (65.8±7.3). It is well known that the incidence of POAF increases with older age, with a rate of 18% when age is less than 60 years and 52% for patients older than 80 years, with an increase of 24% in the odds ratio of developing POAF for every five-year increase in age and a plateau after the age of 80. Fibrosis and dilatation of the atria have been shown to increase with age, with a loss of side-to-side coupling among atrial myocardial cells and consequent slow atrial electrical conduction, which may facilitate the development of atrial fibrillation.5,6,7,8

In our study 81.1% (n=43) of male patients and 18.9% (n=10) of female patients had POAF. Sex-based differences in AF occurrence include differences in the expression of ion channels, hormonal effects on autonomic tone, and in myocardial architecture or fibre orientation.9,10,11,12

There were no significant differences between the groups considering other preoperative factors (HTA, DM, COPD, preoperative TIA/CVI, PAD and smoking) in POAF vs. non-POAF patients. Arterial hypertension was present in 60% of patients with AF in the Framingham Study.13 Hypertension leads to myocardial hypertrophy, with foci of myocardial fibrosis, and favours the dispersion of atrial refractoriness.14,15,16,17 Diabetes mellitus (DM) is another well known predictor for POAF in surgical population as well as in the general one.18 Autonomic neuropathy seems to be responsible for AF in diabetic patients-it blunts parasympathetic activity, allowing for a higher sympathetic excess.18,19,20 Indeed, removal of parasympathetically innervated aortic fat has been demonstrated to increase the risk of developing AF.21 Similarly, smoking interferes with the hyperadrenergic state registered after surgical trauma. Smokers have a higher adrenergic tolerance and are protected against POAF.22 Chronic obstructive pulmonary disease (COPD) may result in arterial hypoxia due to associated ventilation perfusion mismatch.23 Patients with COPD have frequent premature atrial contractions that favour AF development.23, 24, 25 Transient ischemic attack (TIA)/cerebrovascular insult (CVI) and peripheral artery disease (PAD) are also well known risk factors for AF/POAF.

We found no significant difference between the groups in our study considering the preoperative use of amiodarone. Amiodarone has been proved to be useful in the prevention of POAF. Daud et al. randomized 124 patients undergoing elective cardiac surgery to receive oral amiodarone (600 mg/day prior and 200 mg/day after surgery) or placebo for 7 days prior the surgery until the discharge.26 The use of amiodarone was associated with statistically significant (p = 0.03) decrease in POAF incidence (23%) compared to placebo (42%). Redle et al. evaluated 150 patients undergoing CABG in a randomized double blind controlled trial, comparing amiodarone with placebo.27 In amiodarone group, 2000mg of the drug were given in a graduated dosing schedule and then the patients received 400 mg/day beginning on the first postoperative day and continued for seven days. The incidence of POAF was not affected by the prophylactic oral amiodarone and there was no difference between the two groups (p = 0.3). A major study limitation was that the concomitant use of digoxin, calcium-antagonist and beta-blocker was not controlled.

Also, in our study there was no significant difference between study groups considering preoperative use of beta-blockers, but all identified meta-analyses demonstrated that beta-blockers significantly reduced the incidence of POAF.28, 29, 30, 31, 32 Andrews et al. showed that the incidence of POAF decreased from 34% to 8, 7% in patients received beta-blockers. In another meta-analysis of Kowey et al., the decrease in incidence of AF was from 20% to 8, 7%.33 Crystal et al performed the largest meta-analysis based on 27 randomised controlled trials that included 3.840 patients. Especially, the control group presented an incidence of AF approximately 33%, while notably patients receiving beta-blockers had an incidence of 19% [23]. Ferguson et al., in another large retrospective analysis of the Thoracic Surgeons surgical database that included 629.877 patients, observed the morbidity and mortality rate associated with the perioperative use of beta-blockers.34 They revealed a reduction in mortality rate from 3.4% to 2.8% in patients that received peri-operatively beta-blockers. Numerous randomized trials have been conducted so as to evaluate the effectiveness of beta-blockers in the prevention of AF. Lucio et al. randomized 200 patients underwent isolated CABG to receive either metoprolol or no drug.35 Metoprolol was given orally adjusted to maintain optimal heart rate and started from the 12th hour to the 7th postoperative day or hospital discharge. POAF and atrial flutter occurred at 24% in control versus 11% in metoprolol group (p = 0.02).
Several studies compared the efficacy of intravenous (i.v.) or oral beta-blocker as well as different types of beta-blocker. Halonen et al., in an attempt to compare the intravenous with the oral use of metoprolol, randomized 240 patients who underwent first on pump CABG, aortic valve replacement or combined aortic valve replacement and CABG. In both groups, the metoprolol administration was based on heart rate for a 48 hour period. POAF presented a significant decrease (p = 0.036) in intravenous group (16.8%) compared to oral group (28.1%). It should be mentioned that patients at risk to develop complications associated with intravenous metoprolol were excluded.

Moreover, comparison of the effectiveness between metoprolol and carvedilol has also been performed. Acikel et al. randomized 110 patients scheduled for elective CABG to receive either metoprolol (50 mg td) or carvedilol (12, 5 mg td). Therapy was started 3 days prior to surgery and continued in the postoperative period with mean dosages of carvedilol (13 mg daily) and metoprolol (58 mg/day) in corresponding groups. POAF had an incidence of 36.4% in metoprolol compared to 16% in carvedilol group (p = 0.029). Hafgjo et al. randomized 120 patients undergoing CABG to receive metoprolol or carvedilol. In this study, the therapy was started 10 days prior the surgery and initiated with an oral dose of carvedilol 6.25 mg and 25 mg metoprolol twice daily respectively. Then the dosage was increased until the maximum tolerated dose. The incidence of POAF was significantly reduced (p = 0.022) in carvedilol (15%) compared with metoprolol (33%) group. The study presented several limitations: it was a single centre study consisted of small number of patients and thus, inflammation markers such as CRP had not been measured, despite the hypothesis that anti-inflammatory properties of carvedilol may have contributed to increased efficacy.

Kaireviciute et al. showed that digoxin does not show any benefit for POAF prophylaxis (OR 0.97, 95% CI 0.62 –1.49), just like in our study. A subgroup analysis in a meta-analysis of calcium-antagonists found that nondihydropyridines significantly suppressed post-surgery supraventricular arrhythmias (OR 0.62, 95% CI 0.41–0.93), but with a high heterogeneity (p = 0.03). In our study there was not any difference between groups considering the preoperative use of calcium-antagonists. Several studies compared atenolol with other regimens such as digitalis or propafenone. Yazıcıoğlu et al. randomized 160 patients underwent CABG into 4 groups of treatment: a. digoxin and atenolol, b. digoxin, c. atenolol, d. placebo. The combination of atenolol and digoxin (5%) decreased significantly POAF compared with placebo (25%, p = 0.012) but there was no significant difference compared to digoxin or atenolol alone (17.9%, 15.4% p = 0.087). Merrick et al., in SPPAF trial, allocated randomly 207 patients underwent non-emergency cardiac surgery, to receive orally either propafenone 300 mg twice daily or atenolol 50 mg once daily from the first until the 7th postoperative day or until an end point (AF appearance) was reached. The atenolol and the propafenone presented equal efficacy (10, 7% vs. 12%) in the prevention of AF.

Chin et al. investigated whether preoperative angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARBs) use affected the incidence of POAF in patients undergoing off-pump CABG surgery. They concluded that ACEi or ARBs, ACEi alone, and ARBs alone did not favorably influence the occurrence of POAF in patients undergoing off-pump procedure. In our study we have got the same results.

There was no significant difference between our study groups considering preoperative use of diuretics and spironolactone. Bandeali et al. evaluated the influence of preoperative diuretic use in three groups of patients-isolated CABG, CABG plus valve surgery, isolated valve surgery on the appearance of POAF and they concluded that its associated with an increased incidence of new-onset atrial fibrillation (POAF).

Finally, we found that preoperative statin use was associated with a 60% risk reduction in POAF incidence. The antiarrhythmic mechanism of statins can possibly be explained by their effects on inflammation, antioxidant effects, antiarrhythmic effects due to ion channel stabilization, a role in extracellular matrix modulation, an inhibition of synthesis of isoprenoids that are significant for the posttranslational modification of such signalling molecules as Rho, Rac, and Ras, and an ability to reverse angiotensin II-mediated atrial structural remodeling. Ozaydin et al. reported that pre-treatment with statins was protective against the development of POAF (on Kaplan–Meier analysis P = 0.01), but also shortened the duration of POAF episodes (P = 0.0001). The advantage of statin pre-treatment in the suppression of POAF incidence after elective CABG may not depend on type, dose, or duration of use. Nonetheless, negative studies showing no benefit of statins on POAF also exist. For example, pre-treatment with statin prior to cardiac surgery did not show any significant benefit for reducing the risk in the development of POAF. However, this study was conducted retrospectively, and patients received different statins, variable doses were used, and there were incomplete data on the duration of statin treatment prior to cardiac surgery. The first randomized, placebo-controlled trial on statin pretreatment for the reduction of POAF incidence was the ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia after cardiac surgery) trial, which showed a significant decrease in POAF occurrences after pre-treatment with atorvastatin. Moreover, hospital length of stay was shorter in the atorvastatin group compared with placebo (P = 0.001). Of note, there was significantly higher post-operative peak C-reactive protein levels in AF patients compared with those who remained in SR (P = 0.01); however, the ARMYDA-3 trial did not find any statistical association between statin use and plasma C-reactive protein levels. Thus, pretreatment with statin seems to be useful particularly prior to the CABG surgery, despite the small incidences of rhabdomyolysis caused by high doses of statin. A meta-analysis of six randomized studies on the impact of statin treatment on the suppression of AF included two studies with POAF and found that statins were more beneficial in secondary AF prevention rather
in primary prevention and their effect did not appear to be dose-related.\textsuperscript{58}

**Conclusion**

Our results suggest that preoperative use of statins may reduce the incidence of POAF with a 60% risk reduction in POAF incidence in patients undergoing isolated CAGB. We also found that there was no difference in the use of on-pump or off-pump surgery in the POAF vs. non-POAF group.

**References**


Ključne reči: postoperativna atrijalna fibrilacija, by-pass, preoperativna farmakoterapija, statini.